TLDRocket
Sign in

Atlas Bio raises $12.5 million to develop AI simulations for in silico drug trials during Phase II studies

Funding Provisional 86% confidence first seen

Atlas Bio, a Swiss biotech startup, raised $12.5 million to build and expand AI-based in silico simulations of drug trials while it continues Phase II studies. The company says its platform is trained on large-scale RNA readouts and is intended to improve predictiveness, reduce reliance on animal testing, and potentially compress aspects of Phase II timelines.

Atlas Bio Atlas Bio foundational AI model for in silico clinical trials Simon Romanski Creandum First Momentum Ventures Google LEA Partners

The deal

Atlas Bio $12.5 million Other · announced 27 Oct 2026

Investors Creandum First Momentum Ventures LEA Partners

Deal terms as reported in the coverage below.

Source coverage

Swiss startup Atlas Bio secures $12.5M to tackle drug development’s 70% failure rate and move beyond animal testing Tech.eu independent Ex-Google, self-driving engineers’ Atlas Bio raises $12.5M run drug trials as AI simulations Tech Funding News independent

The daily briefing

Every AI story that matters, in your inbox by 8am.

TLDRocket reads all relevant sources, removes duplicate coverage, and summarises the day in two minutes. Follow companies and topics for alerts, or get the briefing in Slack. Free, no spam, unsubscribe anytime.